Feasibility Pilot Study to Evaluate the Safety and Performance of the MEX-CD1 Medical Device in ACLF

NARecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 21, 2024

Primary Completion Date

July 31, 2025

Study Completion Date

October 31, 2025

Conditions
Acute on Chronic Liver FailureMultiple Organ Failure
Interventions
DEVICE

MEX-CD1 Dialysis

"MEX-CD1 is a hyper-chelating colloidal solution that can be added to the dialysate to be used in Slow low-volume continuous veno-venous hemodialysis. One treatment will last 3 hours and 20 minutes.~Patients enrolled are hospitalized in Intensive Care Unit."

Trial Locations (2)

35000

RECRUITING

CHU Pontchaillou, Rennes

69317

RECRUITING

Hôpital Croix Rousse, Service d'hépatologie et gastroentérologie, Lyon

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Slb Pharma

OTHER

lead

Mexbrain

INDUSTRY

NCT06340269 - Feasibility Pilot Study to Evaluate the Safety and Performance of the MEX-CD1 Medical Device in ACLF | Biotech Hunter | Biotech Hunter